Scancell to present at the Biotech Capital Conference

Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of novel immunotherapies for the treatment of cancer, announces that the Company will be presenting at the Biotech Capital Conference on
Thursday 3 March 2016.

Dr Richard Goodfellow will present an update on the Company’s immunotherapy platform technologies:

  • ImmunoBody® - Potent DNA vaccine technology for use in combination with checkpoint inhibitors or as monotherapy for patients with resected disease
  • Moditope® - Novel immunotherapy that destroys tumours and extends survival without the need for checkpoint inhibition

The event will commence at 9.00am at 52 Chiswell Street, London, EC1Y 4SD. Attendance is free, with registration via

The Biotech Capital Conferences are a new institutionally focused platform for listed Biotech companies to reach out to a very active pool of investors. Participants include Biotech investors, investment managers,
private client brokers and analysts who want exclusive access to the management of some of the market’s most interesting, high growth companies.

A recording of the presentation will be available on the Company’s website following the event.

For Further Information:

Dr Richard Goodfellow, Joint CEO Scancell Holdings Plc + 44 (0) 20 3727 1000
Professor Lindy Durrant, Joint CEO    
Charles Breese Larpent Newton +44 (0) 12 8070 3482
Mo Noonan/Simon Conway FTI Consulting + 44 (0) 20 3727 1000




About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer
survival times than when either treatment was used alone.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could
play a major role in the development of safe and effective cancer immunotherapies in the future.